Markets:

Overview

News

Currencies

International

Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.970 -0.190 (-4.57%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024

July 29, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy ↗

July 29, 2024

Piper Sandler downgraded Iovance Biotherapeutics due to a slow launch of Amtagvi (lifileucel), a skin cancer treatment. Despite patient demand, extended treatment timelines and low infusion rates led...

Via Benzinga

Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why. ↗

July 29, 2024

The Federal Reserve's fight against inflation may soon yield financial benefits.

Via The Motley Fool

Topics Economy

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 29, 2024

Via Benzinga

How Is The Market Feeling About Iovance Biotherapeutics? ↗

July 22, 2024

Via Benzinga

What's Going On With Iovance Biotherapeutics Today? ↗

May 24, 2024

On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation data, to be presented...

Via Benzinga

Iovance Biotherapeutics's Options: A Look at What the Big Money is Thinking ↗

May 10, 2024

Via Benzinga

ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗

July 28, 2024

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 23, 2024

Via Benzinga

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 19, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

7 ‘Death Cross’ Stocks That Could Be Contrarian Buys ↗

July 17, 2024

Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position.

Via InvestorPlace

Is Iovance Biotherapeutics a Millionaire Maker? ↗

July 14, 2024

This biotech's future is bright, but how good could it get for investors?

Via The Motley Fool

3 Under-$10 Biotech Stocks That Could Make You Rich ↗

July 11, 2024

Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.

Via InvestorPlace

Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗

July 11, 2024

Via Benzinga

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

June 28, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Is It Too Late to Buy Iovance Biotherapeutics Stock? ↗

June 28, 2024

The stock is down more than 50% from its 52-week high.

Via The Motley Fool

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

June 21, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

3 Top Penny Stocks to Skyrocket Your Wealth in 2024 ↗

June 21, 2024

Find out about the top penny stocks to buy this year for a chance to see incredible results down the road as they soar to new heights.

Via InvestorPlace

The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why ↗

June 10, 2024

New data indicate that its cell therapy could soon find a larger market.

Via The Motley Fool

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

May 29, 2024

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

Via News Direct

Iovance Biotherapeutics to Present at Upcoming Conferences and Events

May 24, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 24, 2024

Via Benzinga

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

May 23, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Bull Market Buys: 2 Growth Stocks to Own for the Long Run ↗

May 22, 2024

These biotech stocks have just launched their first products.

Via The Motley Fool

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 17, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

4 Small-Cap Value Stocks That Could Go Parabolic ↗

May 16, 2024

These four small-cap stocks scan as deeply undervalued right now.

Via The Motley Fool

The 3 Most Undervalued Biotech Stocks to Buy in May 2024 ↗

May 11, 2024

Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns.

Via InvestorPlace

Why Iovance Stock Is Down 18% Today ↗

May 10, 2024

Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 10, 2024

Via Benzinga

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 10, 2024

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.